A new Medical Care Special Commentary names a familiar problem. Medicaid coverage often lags behind clinical need. The article, by Pranav Ayyappan and Dr. Rajesh Balkrishnan, calls Medicaid’s GLP-1 coverage gap “familiar and correctable.”
That title is doing real work.
GLP-1 receptor agonists are often discussed as weight-loss drugs. That is too narrow. These medicines now sit at the center of obesity, diabetes, heart disease, kidney disease, and sleep apnea care. The Medicaid coverage problem is not just about demand. It is about timing. Medicaid may cover costly complications later, while limiting access to treatment earlier.
That is a bad bargain for patients. It may also be a bad bargain for public programs.
The Gap Is Built Into Policy
Medicaid usually covers FDA-approved outpatient drugs from rebate-participating manufacturers. But weight-loss drugs have long sat inside a statutory exception. That exception now matters more than ever. GLP-1 medicines can be covered for diabetes, cardiovascular disease, and sleep apnea. Yet obesity coverage remains optional for states.
This creates a strange divide. A patient may qualify after diabetes develops. Another may be denied while still trying to prevent diabetes. The difference is not always clinical. Often, it is a benefit design choice.
KFF reported that only 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service Medicaid in January 2026. KFF also found that some states had recently dropped obesity coverage. California, New Hampshire, Pennsylvania, and South Carolina had eliminated coverage after earlier survey results. States face real budget pressure. GLP-1 prescriptions and gross Medicaid spending rose sharply after 2019.
KFF estimated that gross Medicaid spending on GLP-1s rose from about $1 billion in 2019 to almost $9 billion in 2024. That number gets attention. It should. But budgets should not stop at the pharmacy counter.
GLP-1s Are Not Just About Pounds Lost
The clinical story has changed quickly. In 2024, FDA approved Wegovy to reduce cardiovascular death, heart attack, and stroke risk in adults with cardiovascular disease and obesity or overweight. FDA also reported that major cardiovascular events occurred in 6.5% of Wegovy users, compared with 8% of placebo users.
In 2024, FDA also approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity. Ozempic is indicated to reduce sustained kidney function decline, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. These are not cosmetic outcomes. They are major health outcomes. They are also expensive outcomes.
CDC estimates that obesity costs the U.S. health care system almost $173 billion each year. The American Diabetes Association estimated diagnosed diabetes cost $412.9 billion in the United States in 2022. Heart disease, stroke, diabetes, kidney disease, and sleep apnea do not appear overnight. They often build slowly.
That is why access matters. Coverage can decide whether treatment starts before the costly event. It can also decide whether patients wait until disease is harder to treat.
Coverage May Not Mean Blank Checks
Public programs need guardrails. No state can ignore the price of these drugs. But “guardrails” should not mean blanket exclusion. A better path would match access to risk. That could include clear clinical criteria. It could include step therapy when appropriate. It could include prior authorization that does not become a maze.
It could also include outcomes tracking. Medicaid programs can ask whether treatment reduces A1c, weight, blood pressure, sleep apnea burden, or cardiovascular risk. The key is to design coverage around value and the goal should be better health, not simply more prescriptions.
A recent JAMA Health Forum study gives a useful clue. States covering obesity-labeled GLP-1s saw higher use of obesity-labeled GLP-1s. But total GLP-1 prescribing did not rise as much as obesity-labeled use. The authors suggested possible substitution between diabetes-labeled and obesity-labeled GLP-1s.
That matters for Medicaid. The budget impact may differ from a simple add-on model. Some patients may switch from one covered version to another. Others may avoid later diabetes treatment if earlier treatment works. That does not prove savings. It does show why blunt coverage decisions can misread the system.
The Equity Problem Is Hard to Miss
Medicaid exists for people with low incomes. It also covers many people with disabilities, complex illness, and unstable access to care. Those are the patients least able to pay cash. When Medicaid does not cover a GLP-1, the drug does not become cheaper. It becomes unavailable. That is where the coverage gap becomes an equity gap.
People with commercial coverage may still face barriers. But some can appeal, switch plans, use savings programs, or pay out of pocket. Many Medicaid patients cannot. The result is familiar. New medical tools arrive. Access follows wealth. Need does not guarantee treatment.
That pattern is not new. But it is correctable.
Prevention Should Count
Medicaid leaders are right to worry about immediate costs. State budgets are real. Pharmacy spending is real. But deferred care also has a price. A heart attack has a price. Kidney failure has a price. Diabetes complications have a price. Severe sleep apnea has a price. Patients pay first. Medicaid pays later.
The policy challenge is not whether every person should receive a GLP-1. The challenge is whether Medicaid can build fair, evidence-based access. That means treating obesity as a chronic disease. It also means recognizing cardiometabolic risk before crisis hits.
A coverage policy should ask a simple question. Who is most likely to benefit, and how can access be protected? For high-risk patients, the answer may be earlier treatment. For Medicaid, that could mean fewer preventable complications later.
A Correctable Failure
The Medical Care commentary frames this as a familiar and correctable failure. That framing feels right. We have seen this before. A treatment becomes available. Evidence grows. Coverage trails behind. Patients with fewer resources wait longest.
The fix will not be simple. Prices must fall. Rebates must be transparent. States need budget help. Clinicians need clear rules. Patients need real access. But the direction is clear.
Medicaid should not only cover disease after it becomes expensive. It should also support treatment when prevention is still possible. GLP-1 coverage is a test of that principle.
The question is not just whether Medicaid can afford these medicines. The question is whether Medicaid can afford to ignore what they may prevent.
Ben King